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Background: Similar to patients with other chronic disor-
ders, patients with serious mental illness (SMI) are often
poorly adherent with prescribed medications. Objective:
We conducted a randomized controlled trial examining
the effectiveness of a pharmacy-based intervention (Meds-
Help) in increasing antipsychotic medication adherence
among Department of Veterans Affairs (VA) patients
with SMI. We also examined the impact of Meds-Help
on psychiatric symptoms, quality of life, and satisfaction
with care. Methods: We enrolled 118 patients from 4 VA
facilities with schizophrenia, schizoaffective, or bipolar dis-
orderwhowereonlong-termantipsychoticsbuthadantipsy-
chotic medication possession ratios (MPRs) <0.8 in the
prior year. Patients were randomized to usual care (UC;
n 5 60) or the pharmacy-based intervention (Meds-Help;
n 5 58). We reassessed adherence at 6 and 12 months, at
which time patients completed Positive and Negative Symp-
tomScales(PANSS),QualityofWell-beingScales(QWB),
and Client Satisfaction Questionnaires (CSQ-8). Results:
Prior to enrollment, Meds-Help and UC patients had
mean antipsychotic MPRs of 0.54 and 0.55, respectively.
At 6 months, mean MPRs were 0.91 for Meds-Help and
0.64 for UC patients; at 12 months, they were 0.86 for
Meds-Help and 0.62 for UC patients. In multivariate anal-
yses adjusting for patient factors, Meds-Help patients had
significantly higher MPRs at 6 and 12 months (P < .0001).
There were no significant differences between groups in
PANSS,QWB, orCSQ-8scores, butpowertodetectsmall
effectswaslimited.Conclusions:Congruentwithpriorstud-
ies of patients with other disorders, a practical pharmacy-
based intervention increased antipsychotic adherence
among patients with SMI. However, SMI patients may re-
quire additional care management components to improve
outcomes.
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Introduction
The long-term use of antipsychotic medications is an es-
sential treatment component for many patients with se-
rious mental illness (SMI).
1 Unfortunately, similar to
patients with other chronic disorders, patients with
SMI are often only partially adherent with prescribed
medications. In a systematic review of 39 studies that
assessed adherence using a variety of methods, approxi-
mately 40% of patients with schizophrenia were partially
or nonadherent with antipsychotic medications.
2 Fully
40% of Department of Veterans Affairs (VA) patients
with schizophrenia obtain less than 80% of the medica-
tion supplies needed to take their antipsychotic doses
continuously.
3 Similarly, almost half of VA patients
with bipolar disorder obtain less than 80% of supplies
needed for continuous use of either antipsychotics or
mood stabilizers.
4,5 Systematic approaches to improving
adherence are needed.
Because partial adherence is a multidetermined phe-
nomenon, there are many potential targets for adher-
ence-enhancing interventions.
2 Depot antipsychotic
medications eliminate the need for daily ingestion of
oral antipsychotics and may increase adherence,
6 but de-
pot medications have not been widely adopted in the
United States, potentially because of concerns about
pain and coerciveness.
7 Psychoeducation programs have
been studied, with researchers finding that simple didactic
1To whom correspondence should be addressed; tel: 734-845-
3649, fax: 734-845-3249, e-mail: marciav@umich.edu.
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727approaches are not as successful in improving adherence
as are individualized, multicomponent, behavioral, and
family interventions.
8–11 However, more complex inter-
ventions are often difficult to deliver, requiring specialized
therapist training or frequent patient or family visits,
and these approaches have not been widely disseminated.
Basedonstudiessuggesting that concreteproblem-solv-
ing approaches accompanied by ‘‘technical’’ aids may be
helpful in improving adherence among patients with
chronic medical conditions,
9–14 we developed a low-
complexity pharmacy-based intervention for patients
with SMI. This intervention was informed by the Health
Belief Model and designed to reduce medication access
barriers and to provide ‘‘cues to action’’ to help patients
remember to refill prescriptions and take scheduled
doses.
15
The primary aim of this study was to assess the effec-
tivenessofthispharmacy-basedintervention, Meds-Help,
in improving antipsychotic adherence among patients
with SMI. Our secondary aims were to examine the ef-
fects of the intervention on patients’ psychiatric symp-
toms, quality of life, and satisfaction with health services.
Methods
The study was registered at ClinicalTrials.gov (Identifier:
NCT00057135), approved by Human Subjects Commit-
teesateachofthe4participatingstudysites,andinvolved
human participants between November 18, 2002, and
September30, 2005. Studydata and findings are reported
in accordance with the Consolidated Standards of
Reporting Trials.
16–18
Figure 1 outlines the recruitment of study participants.
Using VA administrative data, we identified 4394
patients prescribed antipsychotic medications with 2
outpatient mental health visits in the prior 12 months.
Research staff reviewed patients’ chart notes, pharmacy
data, and consulted with their psychiatrists to confirm
that patients met other eligibility criteria, including hav-
ing clinical diagnoses of schizophrenia, schizoaffective,
or bipolar disorder; a treatment plan that included
long-term antipsychotic treatment, antipsychotic medi-
cation possession ratios (MPRs) of <0.8 in the prior
12 months; and no clinical contraindications to study par-
ticipation. Clinical rather than semi-structured research
4394 patients 
screened using administrative 
data and chart review 
837 patients
met all eligibility criteria after review 
of medical charts and pharmacy data 
and consultation with clinician 
604
contacted by study staff 
118
consented and enrolled
60
Randomized to 
Usual Care 
58
Randomized to 
Meds-Help
At 6 months 
56 with MPRs/CAM 
56 with secondary outcomes 
At 12 months 
54 with MPRs/CAM 
49 with secondary outcomes 
outcomes
50 with secondary outcomes 
At 6 months 
59 with MPRs/CAM 
At 12 months 
58 with MPRs/CAM 
49 with secondary outcomes 
315 refused in-person 
interview
18 became ineligible 
before in-person interview 
completed 
117 did not show for 
enrollment appointment 
4 were inappropriate or
ineligible at interview
32 were discovered 
ineligible after interview 
due to MPR >0.8
Fig. 1. Patient Enrollment.
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728diagnoses were used as entry criteria, as clinical diagnoses
are more likely to be used in any clinical implementation.
For patients on more than one antipsychotic, the weighted
average antipsychotic MPR during the prior 12 months
h a dt ob e<0.8.
Patients were excluded if they: no longer appeared to
be in active VA care (eg, no visits in the prior 6 months
andnovisitsscheduledorchartnotesindicatingatransfer
ofcare),werereceivingantipsychoticmedicationsoutside
the VA system, or had a life expectancy of less than
a year. Patients were also excluded if they were receiving
‘‘stronger interventions’’ to promote adherence (eg, the
VA adaptation of Assertive Community Treatment, staff
administration of medications, depot antipsychotics, or
clozapine with its attendant close supervision). Living sit-
uation was not a specific inclusion/exclusion criterion, as
long as paid staff did not assist patients in managing their
medications.
Because of Institution Review Board requirements,
study staff stopped reviewing charts as soon as any exclu-
sion criterion was noted; 837 patients were identified as
potentially eligible for participation. These patients were
sent letters informingthem aboutthe studyandwere sub-
sequently contacted by telephone. Patients who were
interested in participation after a scripted telephone dis-
cussion were invited to an in-person meeting to complete
an informed consent process; 154 patients attended this
in-person meeting.
During the informed consent process, visual aids were
used to explain the key elements of the study, and stan-
dardizedqueriesweremadetoensurethatpatientsunder-
stood these elements. If patients had guardians, their
guardians were informed about the study and consent
forms mailed. Four patients were excluded at this time
because they failed to understand key study elements
or did not have a mailing address or telephone access.
An additional 32 patients were excluded because their
most recent MPR exceeded 0.8.
In all, 118 patients were randomized to UC alone or
UC plus Meds-Help. Randomization was completed cen-
trally at the coordinating site, using a blocked random-
ization scheme by site based on the patient’s level of
adherence in the prior 12 months (MPR of <0.4, 0.4–
0.59, or 0.6–0.79) and the presence of concurrent sub-
stance use. Substance use was considered ‘‘present’’ if
any patient chart note in the prior 12 months indicated
difficultieswithdrugsoralcohol orifthepatientreported
that in the prior 6 months he/she had used any illicit
drugs, had an episode of binge drinking, or consumed
7 drinks per week (for women) or 14 drinks per
week (for men). Site research associates (RAs) called
into the central research coordinator to receive newly en-
rolling patients’ treatment assignment.
UC consisted primarily of treatment in VA outpatient
mentalhealthclinicsandincludedpsychiatristvisits,non-
MD mental health visits, and group visits. During the
study period, patients completed an average of 8 visits
with psychiatrists; 49% had visits with non-MD mental
health clinicians and 23% had group visits.
TheMeds-Helpinterventionconsistedof(1)unit-of-use
packaging that included all patients’ medications for psy-
chiatric and general medical conditions (figure 2), (2)
a medication and packaging education session, (3) refill
reminders mailed 2 weeks before scheduled refill dates,
and (4) notification of clinicians when patients failed
to fill antipsychotic prescriptions within 7–10 days of
a fill date. Meds-Help staff served as contacts for patient
questions regarding pharmacy services or doctors’
prescriptions. Pharmacy technicians, with oversight by
pharmacists, completed many of these intervention
components.
The medication education session was conducted by
a pharmacist, usually in-person, but occasionally by tele-
phone. During this session, the pharmacist reviewed
patients’ prescribed medications, including treatment
indications. The pharmacist also explained unit-of-use
medication packaging (eg, package usage and warning
Fig. 2. Unit-of-Use Packaging.
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pill boxes when medication changes were made by clini-
cians before the next shipment of medication packages.
Measures
The primary outcome measure was medication adher-
ence as measured by the MPR. A more stringent ‘‘com-
posite adherence measure’’ (CAM) was also assessed.
The MPR is the ratio of the number of outpatient days’
supplyofmedicationthatapatienthasreceivedduringthe
designated time period divided by the number of days’
supply they needed to receive to take their prescribed
dose of antipsychotic continuously during noninstution-
alized days. The MPR was the primary outcome measure
because it is based on data (pharmacy fills) that can be
collected unobtrusively, making it less likely to affect ad-
herence behaviors; it can be calculated for patients even
if they stop actively participating in the study; and it is
associated with important outcomes in observational
studies.
3,19
MPRs were calculated for 3 periods: the 12 months
prior to enrollment (baseline), 0–6 months following en-
rollment, and 6–12 months following enrollment, unless
participants had fewer than 90 noninstitutionalized days
in a specified time period because of death, transfer of
care outside the VA, or long-term inpatient stays. If de-
pot antipsychotic medications were instituted after en-
rollment, we did not calculate MPRs after the switch.
Because patients may fill prescriptions but not ingest
their antipsychotic medications, the more stringent
CAM was based on multiple data sources. Patients
were considered adherent on the CAM only if: (1) their
MPR during the study time periods was 0.8, (2) they
reported they ‘‘always’’ took their antipsychotics or
only missed antipsychotics ‘‘a couple of times’’ in re-
sponse to questions from Schizophrenia Outcomes Mod-
ule,and(3)theirbloodtestindicatedthepresenceofsome
antipsychotic medication. The rationale for requiring
patients to meet all 3 criteria is that an indication of
poor adherence on any of these measures is likely asso-
ciated with less-than-optimal adherence. Our a priori re-
search plan was to consider blood levels to be negative
when patients refused blood draws or did not show for
follow-up assessments. If a physician discontinued anti-
psychotic medication because a patient refused it, blood
levels were not drawn and assumed to be negative; if
a physician discontinuedantipsychotics because the med-
ications were no longer considered necessary, the CAM
was assessed only to the point of discontinuation.
Secondary outcomes were psychiatric symptoms as
measured by the Positive and Negative Symptom Scale
(PANSS), quality of life as measured by the Quality of
Well-BeingScale(QWB),andpatientsatisfactionasmea-
sured byClient Satisfaction Questionnaire(CSQ-8) scale.
The PANSS and QWB were completed by the research
associates at each of the study sites. All these scales
are widely used and have demonstrated reliability and
validity.
20–24 Exploratory outcomes included VA psychi-
atric hospitalizations, ascertained through chart reviews.
As with many health services interventions, patients
could not be blinded to study assignment. Research asso-
ciates were also not blinded due to the costs and logistics
ofhiringblindedassessorsforeachsiteand thelikelihood
that assessors would be ‘‘unblinded’’ by patient com-
ments. However, the primary outcomes of adherence
were based on longer term pharmacy fill patterns and
less likely to be affected by subtle biases on the part of
patients or interviewers.
Prior to enrolling patients, RAs received training in
PANSS administration and scoring using standardized
videotapes. RAs also received periodic training during
the study, using tapes of study patients. For the total
PANSS score, the inter-rater reliability, as assessed by
an intraclass correlation coefficient (ICC), was 0.94 for
the first 2 RAs enrolling patients; at a second time point,
theICCwas0.77for4studyRAs,andadditionaltraining
was provided. At a third time point, the ICC for the 4
RAswas0.93.In-personfollow-upassessmentswerecon-
ducted in a private room at the patient’s local VA facility.
Data Analyses
Analyses were conducted on an intent-to-treat basis. We
describe means (6SD) for the continuous MPR measure
and frequencies for the CAM categories (fully adherent/
poorly adherent) at baseline, 6, and 12 months. The pri-
mary outcome of MPR was examined at 6 and 12 months
using multiple linear regression; the CAM was evaluated
as these time points using logistic regression analyses.
Multivariable analyses included the baseline MPR as
a covariate to adjust for levels of adherence prior to en-
rollment. We also adjusted for potential confounding
variables of race, age, psychiatric diagnosis, substance
use, and study site. Analyses for secondary outcomes
of psychiatric symptoms, quality of well-being, and sat-
isfaction were conducted similarly, with multiple linear
regression analyses that adjusted for race, age, psychiat-
ric diagnosis, and study site. The study was powered to
detect a medium-sized effect in the primary outcome of
MPR.
Results
Patient Characteristics
As presented in table 1, mean patient age was 49.9 (SD 6
11.3) years; 97% were men. Sixty patients (51%) were
nonwhite (53 were black, 4 Hispanic, and 3 were Asian);
67% had a diagnosis of schizophrenia or schizoaffective
disorder and 33% had a diagnosis of bipolar disorder.
Approximately 31% had problematic substance use.
Study groups were balanced on all factors, although
the difference between groups in the percentages of
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significance.
Patients were receiving a variety of antipsychotic med-
ications at the time of enrollment with no significant dif-
ferences between groups regarding the agents prescribed.
Olanzapineandrisperidonewerethemostfrequentlypre-
scribed; 35% of intervention and 33% of UC patients
were receiving olanzapine and 42% of intervention and
44% of UC patients were receiving risperidone. At the
time of enrollment, most patients (64%) lived with a part-
ner or family member, 6% lived with friends, 2% lived
in group homes, and 28% lived alone. There were no sig-
nificant differences between groups in reported living
situation.
Enrolled patient attitudes’ toward medications as mea-
sured by items on the Ratings of Medication Influence
Scale were similar to those previously reported for a pop-
ulation of 307 patients with schizophrenia
25; 84%
reportedthatreasonsfora‘‘willingnesstotaketheirmed-
ications’’ included mild or strong beliefs that the medica-
tion made them feel better, whereas 45% reported that
reasons for being reluctant to take their medication in-
cluded distressing side effects.
Study Retention
Because the primary outcome, MPRs, could be calcu-
lated using administrative pharmacy data, we were
able to ascertain this outcome for 56 (97%) of the
Meds-Help and 59 (98%) of UC patients at 6 months
and for 54 (93%) of Meds-Help and 58 (97%) of UC
patients at 12 months. Because MPRs and the CAM
were not calculated for patients who did not have 90
noninstitutionalized days in a follow-up period, MPRs
could not calculated at 6 months for 2 intervention
patients and one control patient and could not be calcu-
lated at 12 months for 4 intervention and 2 control
patients due to deaths, long-term hospitalizations, with-
drawal of consent, or switch to depot medications.
Unlike adherence measures, the secondary outcomes of
thePANSS,QWB,andCSQ-8requiredthatpatientscom-
plete in-person interviews within the appropriate time
frame. These outcomes were calculated for 56 (97%) of in-
tervention patients and 50 (83%) of UC patients at 6
months and for 49 (84%) of intervention patients and
49 (82%) of UC patients at 12 months. Patients missed
in-person interviews for a variety of reasons including
the deaths noted above, no shows or interview refusals,
loss to follow-up, geographic moves, or jail time.
Acceptability and Completion of the Intervention
The intervention was acceptable, with only 7% of inter-
vention patients requesting discontinuation of Meds-
Help. However, an additional 19% did not continue
the intervention for the full 12 months for other reasons,
including death, geographic moves, long-term hospital-
izations,transferringcareoutsidetheVA,switchtodepot
antipsychotics, or physician discontinuation of regularly
dosed antipsychotics. Thus, 74% of the intervention
patients could be considered ‘‘completers’’ of the full
12-month intervention.
Effect of the Intervention on Adherence
Tables 2–4 present the outcomes of our intent-to-treat
analyses. Table 2 presents the unadjusted estimates of pa-
tient outcomes while tables 3 and 4 presents estimates
thatareadjustedforpatientcharacteristicsandstudysite.
At baseline, the mean antipsychotic MPR was 0.54 for
the Meds-Help group and 0.55 for the UC group. At 6
months follow-up, the mean MPR was 0.91 for Meds-
Help patients and 0.64 for UC patients (n 0.26 in
MPR by group). On the more stringent CAM, 50% of
intervention patients and 17% of UC patients met criteria
for adherence at 6 months.
At 12-month follow-up, the mean MPR was 0.86 for
Meds-Help patients and 0.62 for UC patients (n 0.25 in-
crease in MPR by group). At this juncture, 34% of inter-
vention and 18% of UC patients met the criteria for
adherence on the CAM. Patients were characterized as
having a negative CAM for a variety of reasons; most
negative CAMs were the result of failing to meet 2 or
more of the 3 adherence criteria.
As presented in table 3, in multiple linear regression
analyses adjusting for baseline MPR, patient diagnosis,
race, age, problematic substance use, and study site, in-
tervention patients had significantly higher MPRs than
UC patients, both at 6 and 12 months (P < .0001). As
presented in table 4, in logistic regression analyses,
adjusting for the same factors, intervention patients
Table 1. Patient Characteristics (N = 118)
All Control Intervention
P
Value
N or
Mean
%o r
SD
N or
Mean
%o r
SD
N or
Mean
%o r
SD
Mean age
(mean, SD)
49.9 11.3 50.2 11.7 49.6 11.0 .78
Women (N, %) 4 3.4 3 5.0 1 1.7 .33
Nonwhite (N, %) 60 50.8 34 56.7 26 44.8 .20
Diagnosis .06
Schizophrenia
(N,% )
79 66.9 45 75.0 34 58.6
Bipolar (N, %) 39 (33.1) 15 25.0 24 41.4
Substance use
(N,% )
36 (30.5) 19 31.7 17 29.3 0.78
Site 0.60
A( N, %) 34 (28.8) 20 33.3 14 24.1
B( N, %) 26 (22.0) 14 23.3 12 20.7
C( N, %) 21 (17.8) 9 15.0 12 20.7
D( N, %) 37 (31.4) 17 28.3 20 34.5
731
Pharmacy-Based Intervention to Improve Antipsychotic Adherencehad odds ratios of 7.4 and 5.4 for meeting the CAM com-
pared with UC patients at 6 and 12 months, respectively.
Few other factors were significantly associated with
adherence (MPR or CAM) after adjustment for patient
factors and baseline adherence aside from a study site
and nonwhite race which were associated with the
CAM at 12 months.
Effect of the Intervention on Secondary Outcomes
Atbaseline,Meds-HelppatientshadameantotalPANSS
score of 62 and UC patients had a mean total score of 65.
These scores are in the range for what is generally consid-
ered‘‘mildlyill’’forpatientswithschizophrenia.
26Inmul-
tiple linear regression analyses (table 5), differences in
PANSS scores between groups at 6 or 12 months posten-
rollment were not statistically significant. This was true
for the overall PANSS scores and for the positive PANSS
subscale, considered separately. However, the study was
poweredtoassessthesignificanceofmediumsizedeffects,
rather than possible small effects of the intervention on
the positive PANSS score at 6 (0.38) and 12 months
(0.32).
At baseline, Meds-Help patients had a mean QWB
score of 0.59 and UC patients had a mean score of
0.62. These scores are in the range that has been reported
for stable outpatients with schizophrenia.
22,27 In multiple
linear regression analyses, there were no significant dif-
ferences in QWB scores between groups, and effect sizes
were small (0.29 at 6 months and 0.09 at 12 months). At
baseline, intervention patients had a mean total CSQ-8
score of 26 and UC patients had a mean total score of
27, indicating high levels of satisfaction with health serv-
ices. Again, there were no significant differences in mean
CSQ-8 scores at either 6 or 12 months postenrollment,
and effect sizes were small (0.04 at 6 months and 0.11
at 12 months).
Few other patient factors were significantly associated
withsecondaryoutcomesinanalysesadjustingforbaseline
scoresandotherpatientfactors,althoughtherewerestudy
site effects at 12 months for PANSS and QWB and an age
andsubstanceusewereassociatedwithCSQ-8at12months.
Table 2. Adherence and Other Study Measures at Baseline, 6, and 12 Months
Baseline
P Value
6 Months
Bivariate P Value
12 Months
P Value N # or Mean % or SD N # or mean % or SD N # or mean % or SD
MPR (mean, SD)
Intervention 58 0.54 0.20 .7676 56 0.91 0.23 <.0001 54 0.86 0.30 <.0001
Control 60 0.55 0.19 59 0.64 0.33 58 0.62 0.33
CAM criteria (number, %)
Intervention 58 0 0 NA 52 26 50.0 .0003 50 17 34.0 .06
Control 60 0 0 53 9 17.0 51 9 17.7
PANSS positive (mean, SD)
Intervention 58 15.0 5.4 .3101 56 13.5 4.9 .84 49 13.0 4.7 .16
Control 60 16.4 6.0 50 15.6 6.1 49 14.6 5.3
PANSS total (mean, SD)
Intervention 58 62.3 16.3 .492 56 58.8 15.0 .29 49 55.3 14.3 .46
Control 60 64.6 15.0 50 61.7 14.5 49 57.1 12.4
QWB (mean, SD)
Intervention 58 0.59 0.09 .0737 56 0.58 0.09 .27 47 0.60 0.11 .24
Control 60 0.62 0.10 50 0.61 0.12 49 0.61 0.10
CSQ-8 (mean, SD)
Intervention 58 25.9 4.5 .0788 55 27.3 4.3 .96 49 26.4 5.7 .51
Control 59 27.4 3.8 50 27.1 5.0 49 27.0 5.2
Note: MPR, medication possession ratio; CAM, composite adherence measure; PANSS, Positive and Negative Symptom Scales; QWB,
Quality of Well-being Scales; CSQ-8, Client Satisfaction Questionnaires.
Table 3. Effects of Intervention on MPR (Linear Regression
Model)
6 Months 12 Months
b P Value b P Value
Baseline MPR 0.67 <.0001 0.53 .0009
Intervention 0.28 <.0001 0.26 <.0001
Bipolar 0.08 .1906 0.002 .98
Nonwhite 0.06 .2542 0.06 .41
Age 0.004 .0735 0.00003 .99
No substance use 0.09 .0961 0.10 .14
Site B 0.15 .0568 0.05 .59
Site C 0.11 .1319 0.12 .18
Site D 0.18 .0046 0.04 .59
Note: MPR, medication possession ratio.
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UC patients had had a psychiatric hospitalization in the
prior 12 months. In multivariate analyses, there were no
significant differences in the likelihood of a psychiatric
hospitalizationat12monthspostenrollment.Inanexplor-
atory ‘‘completer’’ analysis (n = 87), results were similar to
those reported for the intent-to-treat analyses, except the
difference in positive PANSS scores was significant in
unadjusted (but not adjusted) analyses at 6 months.
Adverse Events
One of the 2 deaths in the 12-month study period was in
the intervention group and was considered ‘‘possibly’’ re-
lated to the intervention. This death was attributed to in-
toxication with cocaine, citalopram, and nortriptyline.
The patient had had no changes in amitriptyline refilling
patterns in the 11 months prior to death, and the medi-
cationwasprescribedinusualdoses.Thehighmedication
levels may have occurred for a number of reasons (inten-
tional overdose, counterbalancing of a cocaine high with
amitriptyline, etc.). However, if the patient ingested his
amitriptyline more regularly with the intervention and
was a slow metabolizer, this may have contributed to
high nortriptyline levels. The data safety monitoring
board and local IRBs reviewed this event and allowed
thestudytocontinuewithoutchange.Nohospitalizations
during the study were deemed related to the intervention.
Discussion
We found that a low-complexity pharmacy-based inter-
vention improved antipsychotic adherence among
patients with SMI, a patient population in which poor
adherence is common. The differential increase in
MPR among Meds-Help patients compared with UC
(D 0.25 MPR) was consistent with that previously
reported for patients with diabetes and hypertension
who received unit-of-use packaging and refill reminders
for oral hypoglycemic and antihypertensive medica-
tions.
12,13 Thus, a pharmacy-based intervention with
these components appears to be as effective in increasing
adherence for patients with SMI as for patients with
other chronic medical conditions.
Although there was a site difference in the impact of
the Meds-Help measure on one measure of adherence
(CAM) at 12 months, multivariate analyses that con-
trolled for site suggest that the Meds-Help program
had a positive impact on adherence (MPR and CAM),
even when site differences in pharmacy staffing and pro-
cedures were taken into consideration.
Table 4. Effects of Intervention on Composite Adherence
Measure
6 Months 12 Months
OR 95% CI OR 95% CI
n 0.1 Baseline MPR 1.90 (1.31, 2.75) 2.51 (1.49, 4.21)
Intervention 7.40 (2.59, 21.16) 5.41 (1.61, 18.12)
Bipolar 0.58 (0.17, 2.01) 0.44 (0.11, 1.79)
Nonwhite 1.52 (0.47, 4.89) 4.28 (1.04, 17.61)
Age 1.01 (0.96, 1.05) 1.03 (0.97, 1.08)
No substance use 1.58 (0.51, 4.94) 2.73 (0.76, 9.80)
Site B 0.34 (0.07, 1.59) 0.44 (0.08, 2.30)
Site C 0.50 (0.10, 2.47) 0.06 (0.01, 0.63)
Site D 1.05 (0.28, 3.86) 1.14 (0.26, 4.99)
Note: OR, odds ratio; CI, confidence interval; MPR, medication
possession ratio.
Table 5. Effects of Intervention on Secondary Outcomes
6 Months 12 Months
b P Value b P Value
PANSS
Baseline PANSS 0.68 <.0001 0.58 <.0001
Intervention 1.71 .42 0.95 .67
Bipolar 4.17 .10 0.30 .91
Nonwhite 0.41 .87 0.64 .79
Age 0.06 .57 0.04 .74
No substance use 1.95 .41 1.49 .53
Site B 3.07 .35 1.73 .61
Site C 2.05 .55 8.76 .02
Site D 1.44 .60 2.74 .34
Positive PANSS
Baseline PANSS 0.65 <.0001 0.57 <.0001
Intervention 1.16 .18 0.28 .75
Bipolar 0.39 .70 0.75 .48
Nonwhite 0.88 .37 0.56 .57
Age 0.02 .67 0.02 .65
No substance use 0.57 .56 0.30 .76
Site B 0.24 .85 0.67 .63
Site C 0.03 .98 2.61 .07
Site D 1.12 .31 0.56 .62
QWB
Baseline QWB 0.51 <.0001 0.63 <.0001
Intervention 0.01 .76 0.01 .65
Bipolar 0.03 .10 0.03 .21
Nonwhite 0.02 .28 0.005 .79
Age 0.002 .08 0.001 .25
No substance use 0.02 .23 0.002 .91
Site B 0.03 .27 0.04 .10
Site C 0.03 .31 0.06 .04
Site D 0.05 .04 0.05 .03
CSQ-8
Baseline CSQ8 0.60 <.0001 0.69 <.0001
Intervention 1.36 0.09 0.77 .39
Bipolar 1.28 0.18 1.15 .28
Non-White 0.17 0.85 1.76 .08
Age 0.04 0.34 0.11 .02
No Substance Use 1.58 0.07 2.90 .003
Site B 1.62 0.20 2.11 .14
Site C 0.16 0.89 1.04 .45
Site D 0.42 0.68 1.13 .33
Note: PANSS, Positive and Negative Symptom Scales; QWB,
Quality of Well-being Scales.
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Pharmacy-Based Intervention to Improve Antipsychotic AdherenceThe increase in adherence observed with Meds-Help is
also congruent with a recent study examining a phar-
macy-based intervention for elderly patients with coro-
nary risk factors who were taking 4 medications.
This intervention included unit-of-use packaging along
with bimonthly visits with a clinical pharmacist. During
the study’s observational phase when all study partici-
pants received the intervention, the percentage of medi-
cations taken increased from 61% to 97%; during
asubsequent phase whenthe intervention was withdrawn
for randomly selected patients, those who continued to
receivetheinterventionsustainedhighlevelsofadherence
while those who were withdrawn from the intervention
returned to taking 69% of prescribed medications.
28
The current study and these prior studies suggest that
health systems should consider pharmacy-based inter-
ventions for patients with chronic conditions and poor
adherence. Although the ‘‘active’’ ingredients in these
studies’ multicomponent interventions cannot be posi-
tively identified, the Meds-Help intervention was based
oncomponentsofHealthBeliefModel,andbothreduced
access barriers and provided strong visual and written
cues for action (through unit-of-use packaging and
mailedrefillreminders).Thus,studyresultsareconsistent
with cues to action and the reduction in access barriers
improving adherence. A recent systematic review
reported evidence for the effectiveness of unit-of-dose
packaging in improving adherence among patients
with a variety of medical conditions.
29
In this study, pharmacy technicians completed most of
the prescription tracking and packaging. Although phar-
macy technicians have relevant training and are lower
cost than many health system employees, they have sel-
dom been incorporated into mental health and other
chronic care teams. Further utilizing these personnel to
provide pharmacy-based services may be an affordable
avenue for health systems attempting to address the
chronic problem of adherence.
Secondary Symptomatic Outcomes
Given numerous observational studies reporting a strong
association between higher levels of antipsychotic adher-
enceanddecreasedpsychiatrichospitalization,
3,30wehad
expected that symptomatic improvements would accom-
pany increases in antipsychotic adherence. Unfortu-
nately, we were not able to demonstrate significant
improvements in symptoms, although we were under-
powered to assess small effects.
A recent comprehensive review of adherence-enhanc-
ing RCTs in a variety of medical disorders reported
that only a minority of studies showed both an increase
in adherence and accompanying changes in symptomatic
outcomes.
31Our studyfindingsare congruentwithrecent
study of a more intensive adherence-enhancing interven-
tion for patients with schizophrenia, medication-focused
cognitive adaptation training (Pharm-CAT).
32 Patients
who received Pharm-CAT also had significant improve-
ments in antipsychotic adherence along with some func-
tional improvements; however, they did not experience
greater reductions in positive psychotic symptoms com-
pared with UC patients.
32
There are several potential explanations for findings of
increased adherence without an accompanying finding of
significant symptom improvement. Potentially, patients
may have refilled their medications more regularly
with Meds-Help but failed to increase their medication
ingestion. However, our a priori CAM included compo-
nentsrelatedtoingestionandstillshowedrobustincreases
with the intervention. In addition to patients with schizo-
phrenia, we included patients with bipolar disorder on
long-term antipsychotics. These patients had lower levels
of psychotic symptoms at baseline, which could poten-
tially limit our ability to detect symptomatic changes.
However, decreases in PANSS scores from baseline to
12 months were similar for patients with schizophrenia
and bipolar disorder. We note that the increase in overall
dose from improved adherence may simply have been too
small to impact symptoms (25% more outpatient days
with medications ‘‘on hand’’), the follow-up period may
have been too short to fully capture the benefits of in-
creased adherence, or the relatively stable outpatients en-
rollinginthisstudymayhavebeenreceivingthemaximum
benefit from their antipsychotic medications despite in-
complete adherence. Patients with SMI may need broad-
er-based interventions than those focused on medication
adherence if their outcomes are to be improved.
Other Limitations
Measures of adherence in this study are approximations
of actual adherence behaviors. A direct measure of
patients’ medication taking behavior would be the ulti-
mate goldstandard butis seldom achievablein adherence
research.
33 Although our participation rate is similar to
that of most RCTs, patients recruited into a randomized
trial may not be typical of all patients with SMI. More
paranoid patients or those who were completely unwill-
ing to take medications may have been underrepresented
in the study sample—and this should be considered when
generalizing study results to clinical populations. How-
ever, study participants’ reported attitudes toward anti-
psychotic medications were similar to those reported for
another population of patients with schizophrenia.
25
Our study was not double blind, and a blinded assess-
ment of outcomes would have been desirable. However,
primary study outcomes were based on longer term pat-
terns of medication filling which may be less susceptible
to subtle biases on the part of interviewers or patients.
Summary
We found that a low-complexity pharmacy-based inter-
vention increased antipsychotic adherence among
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M. Valenstein et al.patients with SMI. This finding is congruent with several
studies that have reported improved adherence with pre-
scription tracking and unit-of-dose packaging by phar-
macy personnel for patients with other chronic
illnesses. The intervention is feasible in clinical practice
and is now implemented in 5 facilities in Veterans Inte-
grated Services Network 11. Health systems may find
this an affordable and logistically feasible method for
addressing poor adherence among their patient popula-
tions. However,toimprovethe outcomes ofpatients with
SMI, additional chronic care management components
may be needed.
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